



CLEARPOINT®
NEURO

WHEN YOUR PATH IS UNCLEAR,
WE POINT THE WAY.™

Nasdaq: CLPT

May 2021



FORWARD LOOKING STATEMENTS


Statements herein concerning the Company's plans, growth and strategies may include forward-looking statements within the context of the federal securities laws. Statements regarding the Company's future events, developments and future performance, as well as management's expectations, beliefs, plans, estimates or projections relating to the future, are forward-looking statements within the meaning of these laws. Uncertainties and risks may cause the Company's actual results to differ materially from those expressed in or implied by forward-looking statements. Particular uncertainties and risks include those relating to: the impact of the COVID-19 pandemic and the measures adopted to contain its spread; future revenue from sales of the Company's ClearPoint Neuro Navigation System products; and the Company's ability to market, commercialize and achieve broader market acceptance for the Company's ClearPoint Neuro Navigation System products. More detailed information on these and additional factors that could affect the Company's actual results are described in the "Risk Factors" section of the Company's Annual Report on Form 10-K for the year ended December 31, 2020, and the Company's Quarterly Report on Form 10-Q for the three months ended March 31, 2021, both of which have been filed with the Securities and Exchange Commission.

ClearPoint Neuro: Two Opportunities, One Platform



A Biologics & Drug Delivery Company with a Broad Portfolio of Pharma Partners and Indications with Potentially Explosive Growth

- \$1B+ Potential Market, first indication expected in 2022
- 2020 Growth of 109% during COVID



A Medical Device Company with an Innovative and Expanding Portfolio Supported by an Established On-Site Clinical Channel

- \$500M+ in Existing Market Opportunity
- 5+ New Products Expected in next 2 Years

ClearPoint Neuro: A Proven Platform

Key Products: **FDA** **CE** Marked Platforms

HEADQUARTERS
Solana Beach, CA

MANUFACTURING
Irvine, CA

EUROPEAN HEADQUARTERS
Manchester, UK


2020 REVENUE
\$12.8m

CASH
\$64.9m^(A)

U.S. PATENTS ISSUED
65

GROSS MARGIN^(A)
65%

EMPLOYEES
65+
28+ field
37+ production & development



(A) As of, and for the quarter ended, March 31, 2021

Limitations of Traditional Stereotactic Neurosurgery


Lack of Real-Time Image Guidance

PRIMARY CHALLENGE

For minimally invasive procedures to be successful, the surgeon needs imaging to see into the head

MRI is the best imaging tool for the brain

Large, metallic frames are not MRI compatible




Big Iron companies like Siemens and Philips are innovating to make interoperative MRI scanners more accessible



Our Platform – Procedure Overview



The ClearPoint® Neuro Navigation System



Leverage live MR Imaging to **Decide, Guide, Treat and Confirm** with sub-millimetric accuracy.



Our Platform

SmartFrame® XG



SmartFrame XG Trajectory Tower with ClearPoint 2.0 Software

SmartFrame Array™





SmartFrame Array Tower* with "virtual array" Software and next generation robotic system with increased automation and enabling software

Our Platform

The ClearPoint 'Maestro' Brain Model* Licensed and Jointly Developed with Philips

1. Shape Constrained, triangular mesh model enables point-based correspondence across multiple subjects
2. Fast and capable of peri-procedural imaging without CPU acceleration
3. This model is the basis for future navigation tools across Biologics & Drug Delivery, DBS Navigation, Laser Ablation and more.



Our MRI-guided therapy platform is currently being used to...

CLPT PLATFORM RUNS ON ALL MAJOR SCANNERS

DELIVER BIOLOGICS AND DRUGS

IMPLANT NEURO STIMULATION LEADS

PLACE LASER ABLATION PROBES

SIEMENS



PHILIPS

IMRIS 



LYSOGENE

uniQure


charles river

...with 30 total commercial and academic partners

Medtronic



Boston Scientific



Medtronic
VISUALASE

MONTERIS
MEDICAL

Broad and Growing User Base of Leading Neurosurgery Centers

60+ Centers in the US, Canada and EU... and Growing Globally

UC San Francisco
Stanford University
Stanford Children's Hospital
UCSF Benioff Children's
San Francisco VA
USC Keck Hospital
UC San Diego
Mayo Clinic Phoenix
University of Colorado
University of Utah
University of Arizona
Banner Health Tucson
Cook Children's Hospital
Texas Children's Hospital
MD Anderson Cancer Center
Houston Methodist Hospital
Univ. Kansas Medical Center
Dallas Presbyterian Hospital
Willis-Knighton
Oklahoma State University
Cincinnati Jewish
Children's National

University of Wisconsin
University of Michigan
University of Minnesota
Cincinnati Children's Hospital
Ohio State University
Cleveland Clinic
Northwestern Central DuPage

Charles River Labs (*Laval, Canada*)
Nationwide Children's
Children's Mercy Hospital
CHOA Scottish Rite
Le Bonheur
INOVA Fairfax
Carilion Clinic

Rigshospitalet (*Copenhagen, Denmark*)
Johns Hopkins University
Yale University
Boston Children's Hospital
Weill Cornell
Brigham & Women's
Massachusetts General Hospital
National Institutes of Health
Memorial Sloan-Kettering
Dartmouth-Hitchcock
Mt. Sinai West
Beth Israel Deaconess
Children's of Philadelphia
UPMC
Hos. Univ. of Pennsylvania
Hackensack Univ. Med. Center
University of Virginia
Children's of Alabama
Duke University
Tampa General Hospital
Mayo Clinic Jacksonville
Emory University

100+
Centers
Expected
by 2025

Biologics & Drug Delivery


1. Biologics & Drug Delivery

Why ClearPoint?

Benefits of ClearPoint

1. Select and confirm the most accurate trajectory before insertion using live MRI Guidance
2. Identify peri-procedural safety issues live instead of after the patient is closed (i.e., hemorrhage)
3. Confirm proper target coverage with drug before closing the patient


***Every Clinical Trial Patient is Crucial.
Why Take Any Chances?***



Only ClearPoint combines real-time direct imaging software and hardware to allow intra-procedural adjustment by the Neurosurgeon

1. Biologics & Drug Delivery

Estimated \$1.5B* Market Opportunity As Platform for Gene Therapy




1. PTC Therapeutics Webcast at 38th Annual J.P. Morgan Healthcare Conference Jan 15, 2020, 2. Lysogene Corporate Presentation at 38th Annual J.P. Morgan Healthcare Conference on Jan 13, 2020 3. Voyager Therapeutics January 2020 Corporate Presentation. 4. Arthur KC, et al. Projected increase in amyotrophic lateral sclerosis from 2015 to 2040. Nat Commun. 2016; 7:12408. 5. <https://www.aans.org/en/Patients/Neurosurgical-Conditions-and-Treatments/Glioblastoma-Multiforum>. 6. <https://digregistry.org/patients-families/about-dig/>. 7. <https://emedicine.medscape.com/article/1154583-overview#a6>.

* Addressable market based on potential case volume for near-term programs slated to launch before 2025. Does not include long-term opportunities for Glioblastoma and ALS.

1. Biologics & Drug Delivery

Specialized Consultation for Pharmaceutical Customers



Navigation Device & Therapy

2. Neuro Navigation (DBS)

Deep Brain Stimulation

Deep brain stimulation (DBS) uses a surgically implanted medical device, similar to a cardiac pacemaker, and leads to deliver controlled electrical stimulation to precise targeted areas in the brain.



The ClearPoint® Neuro Navigation Platform is used to accurately place leads in the appropriate targeted structure. The leads are connected in a separate procedure to a neurostimulator implanted near the collarbone.

2. Neuro Navigation (DBS) Deep Brain Stimulation

Gaining Share in a Growing Market




Boston
Scientific

Medtronic

Abbott

NEUROPACE

Parkinson's Patient Population (US)




Total Current Addressable U.S. Market

6,000 x \$12,000 / case = \$72M
(Navigation & MER)

Growing 10%

2. Neuro Navigation (DBS)

Improved Navigation & Technology, New Indications Drive DBS Market Growth of 10%+ CAGR 2020-2025




3. New Therapy Devices

ClearPoint Neuro Laser Therapy – Capturing the Entire Procedure


LITT uses laser energy to destroy unwanted cells

- Today MRI is required during LITT procedures to precisely monitor and control the temperature and thermal dose from that laser.
- ClearPoint is chosen by Neurosurgeons for the most difficult Neuro LITT cases today.
- One clinical support team and a simplified iMRI workflow will accelerate growth.
- ClearPoint has partnered with CLS and IGT to develop an optimized laser and thermometry system to capture the entire procedure.



INFLEXION™ Head Fixation Frame

ClearPoint Compatibility Kits



TRANBERG® Laser



Innovative laser fiber technology designed to optimize heat distribution, eliminate external cooling, and help reduce procedure times. FDA cleared, CE Marked for non-neuro applications.


3. New Therapy Devices

ClearPoint Neuro Laser Therapy* – Capturing the Entire Procedure


Significant Addressable Neuro Market in Epilepsy and Tumor




LiTT for Epilepsy - Total Addressable Patient Population (US)



LiTT for Tumors - Total Addressable Patient Population (US)



Navigation
(\$6,000)



Laser Applicators
(\$12,000)

Total Current Addressable Market
 $20,000 \times \$18,000 / \text{case} = \360M
(Navigation & Laser Applicators)

2020
1,200
 Actual LiTT Procedures Today (est)
 ClearPoint used in 30%

Growing 20+%

New Global Showcase Site


















ClearPoint Cove Training and Innovation Center – Solana Beach, CA



- Intimate training experience for surgeons and staff to perform mock procedures and provide pipeline feedback
- Showcase new technology for Pharmaceutical Drug Delivery partners
- Home for remote support specialists to reduce travel for simpler procedures




Accelerated Product Pipeline and Target First Clinical Use

	2020-21	2022	2023
Navigation & Robotics	 <p>Inflexion™ Head Fixation Frame</p>  <p>SmartFrame Array™1</p>	 <p>ClearPoint Neuro Navigation Software v. 2.1²</p>  <p>ClearPoint Maestro™ Brain Model²</p>	 <p>ClearPoint Maestro™ Sub Nuclei App²</p>  <p>Robotic-Assisted Navigation²</p>
Biologics & Drug Delivery	 <p>Pre-Clinical & Clinical Support Services</p>	 <p>Pre-Clinical Head Fixation Frame²</p>  <p>ClearPoint Maestro™ Infusion Modeling App²</p>	 <p>Orchestra™ Head Fixation Frame²</p>  <p>ClearPoint Maestro™ Infusion Targeting App²</p>
Therapy and Enabling Technology	 <p>5F and 7F Peel-Away Sheath Kits</p>  <p>Bladed Lancet</p>	 <p>Laser Ablation System w/ ThermoGuide²</p>  <p>Biopsy Needle²</p>	 <p>Micro-Electric Recording System (MER)²</p>  <p>“Smart” Biopsy Needle²</p>

4 Pillar Growth Strategy by 2025

Target Indications of > 150,000 procedures per year represents
Potential Addressable Market for CLPT of \$1B+



GLOBAL SCALE

Expand Footprint OUS
Open WW Training / Remote Support Facility
Launch Robotic Platform

4

NEW THERAPY DEVICES

Launch Maestro Brain Model and Apps
Enter Laser Ablation Market
Build 'Smart' Biopsy Market

3

DBS Navigation

Enter the MER Market, Expand into the Operating Room
Participate in Trials for new DBS indications
Achieve 'Asleep' Indication and Market Directly to Patients

2

BIOLOGICS & DRUG DELIVERY

Accumulate Global Partners, Diverse Indications
Expand Translational & Clinical Services
Execute on Development Pipeline

1



2020

2025

Financials

2013 - 2021

Growth in Case Volume and Revenue



Executive Summary



Unique Platform technology

enabling Precision MRI-Guided Therapies to restore quality of life for some of the most debilitating disorders




Pipeline of new revenue streams

from product improvements, biologic and drug delivery partnerships, and standalone therapy products



Procedure volume has grown

33%+ CAGR from 2013-2019




Total potential addressable market

> \$1B for our products and pipeline



Large, Growing installed

base in 60+ of 250+ leading Neurology clinical and research centers in U.S., Canada and Europe



A passionate team

of embedded scientists and specialists





CLEARPOINT®
NEURO

